Representative Stakeholder Priority Areas
Representative Priorities or Interest Areas
Public Sector: Health agencies; preparedness and response units; public health units; regulatory agencies; basic research divisions; domestic and foreign policy agencies; and military.
• Disease burden and health impact.
• Non-market and non-economic benefits of vaccines.
• Costs relating to vaccine development and delivery.
• Long-term benefits to the vaccine development enterprise, including (a) effective combination vaccines and (b) strategies to optimize existing or new production and delivery platforms.
• Ability to produce and administer a vaccine promptly for novel threats.
• Innovative methods for administration, including self-administration.
• Vaccines with long shelf life and ease of storage and management.
• Low number of doses and longevity of protection.
• Development of tracking systems from manufacturing plant to recipients in the field.
• Development of a scientific base for a new vaccine.
• Budgetary constraints for new vaccine research and development.
• Programmatic and operational aspects of administering new vaccines.
• Fitting new vaccines into existing vaccination schedules.
• Building harmony among general public, medical community, public health community, research community, manufacturers, and other international partners.
• Identification of disease and vaccine candidates that should not be prioritized.
Private Sector: Vaccine and biopharmaceutical industry.
• Development of desired product profiles that clearly describe target population and subpopulation segments, potential indications, and key product attributes.
• Consideration of uncertainty around licensure and identify clinical endpoints that will be used by regulators to assess vaccine efficacy, adjuvants, and key product attributes.
• Global need for certain vaccines with volume and price considerations.
• Financial burden due to clinical trials and barriers to successful licensing of a vaccine.
• Cost of development and projected time to economic return.
• Status of competition for a vaccine in developing and developed country markets.